Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Plasma cell 1Lymphoid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Melanoma 137Carcinoma, Non-Small-Cell Lung 38Carcinoma, Renal Cell 33Neoplasm Metastasis 32Prostatic Neoplasms 22Brain Neoplasms 21Lung Neoplasms 20Pancreatic Neoplasms 19Uveal Melanoma 17Neoplasms 17Carcinoma, Hepatocellular 13Breast Neoplasms 13Sarcoma 12Skin Neoplasms 10Kidney Neoplasms 10Urinary Bladder Neoplasms 9Squamous Cell Carcinoma of Head and Neck 9Glioblastoma 9Triple Negative Breast Neoplasms 8Ovarian Neoplasms 8Colorectal Neoplasms 8Carcinoma, Transitional Cell 8Small Cell Lung Carcinoma 7Multiple Myeloma 7Colonic Neoplasms 7Clear-cell metastatic renal cell carcinoma 7Recurrence 6Myelodysplastic Syndromes 6Diabetes Mellitus, Insulin-Dependent, 12 6Uterine Cervical Neoplasms 5

Interventions

Cyclophosphamide 81fludarabine phosphate 77Peripheral Blood Stem Cell Transplantation 62Mycophenolic Acid 55Tacrolimus 54Whole-Body Irradiation 52Busulfan 51Antilymphocyte Serum 45Cyclosporine 41fludarabine 36Methotrexate 32Filgrastim 32Melphalan 30Radiotherapy 25Methylprednisolone 19Cytarabine 17Cord Blood Stem Cell Transplantation 17Sirolimus 15Azacitidine 15Granulocyte Colony-Stimulating Factor 14Alemtuzumab 14thymoglobulin 13Flow Cytometry 13Etoposide 13Cyclosporins 13Specimen Handling 10Biopsy 10Thiotepa 9Psychiatric Rehabilitation 9Decitabine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Myeloproliferative Disorders × Ipilimumab × Clear all
NCT03912064 2026-01-05

A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
25 enrolled 17 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡